813MO Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: The SOLO2/ENGOT Ov-21 trial. - Frenel, J-S.; Kim, J-W.; Berton-Rigaud, D.; Asher, R.; Vidal, L.; Pautier, P.; Ledermann, J.A.; Penson, R.T.; Oza, A.M.; Korach, J.; Huzarski, T.; Pignata, S.; et al. (Annals of Oncology, 2020)